These results support previous reports of intratumoral heterogeneity for MGMT methylation levels and the possibility that reliance on a single biopsy specimen may not provide an accurate consensus of MGMT methylation for the tumor, reducing the clinical value of this biomarker. Here, MGMT is linked to neoplasm.